Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ArriVent BioPharma is at the centre of one of biotech's sharpest single-week collapses, with a delayed pivotal readout stripping nearly half the stock's value in two days and leaving analysts scrambling to reset targets they had set above $40 just weeks earlier.
The catalyst is FURVENT. The Phase 3 trial of firmonertinib in EGFR exon 20 insertion NSCLC has still not reached its required event count, pushing the readout further into the second half of 2026 and adding a 4-to-6 week lag for database lock and quality control. The stock closed at $15.09 on October 6, down 47% in one day and roughly 49% on the week. That move dwarfs the losses seen elsewhere in the small-cap biotech universe: peers NKTR and TSHA fell 33% and 12% respectively on the week, but neither is close to AVBP's scale of damage. The concern driving the selloff is not just timing. Bears argue that the delay implies the firmonertinib arm is not separating from the control arm as fast as hoped, and that a sub-8-month PFS result could leave ExOn 20 adoption in the US well below initial projections.
The positioning picture heading into the reset is notable. Short interest already ran at 22.1% of free float before the drop, up about 8% over the past month, a level that had been building quietly as FURVENT's timeline stretched. Despite the crash, the borrow market has not tightened dramatically: availability is around 100%, meaning roughly one share is available for every one already lent out, well off the tightest point of the past year at 24.9%. Cost to borrow has risen 36% on the week to 0.80%, but remains low in absolute terms, consistent with a stock where shorts were already well-established rather than scrambling to find new supply. The ORTEX short score is elevated at 80, down from 83 earlier in the week, suggesting some short-side pressure eased as positions were covered or reset after the move. Options positioning is notably call-heavy: the put/call ratio is just 0.19, barely above its 20-day mean of 0.18 and near the low end of the 52-week range. That tells you the options market was not braced for this outcome.
Every analyst who has updated their models this week has kept their Buy rating but slashed their price target. Citigroup moved from $40 to $20. Truist Securities and Guggenheim both cut from $45 to $18. BTIG trimmed from $42 to $29. The consensus mean target now sits at $33.30, implying more than 100% upside from current levels on paper, but that figure reflects targets set minutes after the news, not the settled view of a Street that has had time to reassess. The bull case remains intact in structure: firmonertinib has shown 78.6% ORR in exon 20 disease and 68% confirmed ORR in PACC mutations, the company ended Q2 with $373 million in cash providing runway into 2028, and additional pipeline assets in ALPACCA, ARR-217, and ARR-002 offer longer-term options. The bear case is that the control-arm context from WU-KONG28 and EXCLAIM-2 makes the delay difficult to explain away, that competitive pressure is building, and that any financing needed before a readout would likely come at punishing terms. The short score rank sitting in the 2nd percentile and a days-to-cover of nearly 18 days (per the most recent FINRA settlement data) underscore how convicted shorts have been in this name for months.
On the ownership register, OrbiMed Advisors filed a Schedule 13D on this stock in August 2025, placing an activist holder on the register at a disclosed 7.5% stake. That is one of the more significant structural facts about AVBP: an activist-flagged holder at a meaningful size, though stakes are as last disclosed and positions can fall below 5% without a further filing. BlackRock added 720,000 shares in the quarter to September 30, and FMR added 144,000. Whether institutional holders step in to absorb selling after a 49% weekly decline, or whether they trim exposure given the trial setback, will show up in the next round of filings. Wikipedia page views for the stock registered a z-score of 4.6 against its own 90-day history as of late September, a measure of retail attention that was already running hot before the news broke.
The next scheduled earnings print is November 12. Between now and then, the only datapoint that matters is whether ArriVent provides any update on FURVENT's event-accrual progress, and whether any of the institutional holders with positions above 5% file amendments to their 13D or 13G positions.
See the live data behind this article on ORTEX.
Open AVBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
